OM336 in Seropositive Autoimmune Diseases
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorOuro Medicines
About this trial
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of OM336 in adult participants with seropositive autoimmune diseases. OM336 is administered subcutaneously in ascending dose cohorts.
Eligibility criteria
Qualifiers
Diagnosis of active seropositive autoimmune disease
Relapsed/refractory after ≥2 prior/ongoing treatments
Body weight ≥ 50 kg
Willing to comply with and study requirements and procedures
Disqualifiers
Previous treatment with a BCMA-targeted therapy
Clinically significant infection within 3 months of screening
Major surgery within 3 months of screening or planned during the study
Pregnant or breastfeeding
Trial design
Treatments tested in this trial
- OM336
Treatment groups
39 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov